Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Clinical evaluation of fitness to drive in patients with brain metastases
Gorelkin, Vanessa C, Mrugała, Maciej M. , Vora, Sujay A., Ashman, Jonathan B. , Daniels, T.B., Halyard, Michele Y. , Rule, William G., Butterfield, Richard , Porter, Alyx B. , Valencia-Sánchez, Cristina , Daniels, Thomas B, Butterfield, Richard J, Schild, Steven E. , Sharma, Akanksha , Zhang, Nan

Mayo Clinic

Neuro-Oncology Practice | July 3, 2019 | Volume: 6 | Issue: 6 | Pages: 484-489

10.1093/nop/npz027 | PMID 31832219 Get It

Abstract Background Guidelines to provide recommendations about driving restrictions for patients with brain metastases are lacking. We aim to determine whether clinical neurologic examination is sufficient to predict suitability to drive in these patients by comparison with an occupational therapy driving assessment (OTDA). Methods We prospectively evaluated the concordance between neurology assessment of suitability to drive (pass/fail) and OTDA in 41 individuals with brain metastases. Neuro-oncology evaluation included an interview and neurological examination. Participants subsequently underwent OTDA during which a battery of objective measures of visual, cognitive, and motor skills related to driving was administered. Results The mean age of patients who failed OTDA was age 68.9 years vs 59.3 years in the group members who passed (P = .0046). The sensitivity of the neurology assessment to predict driving fitness compared with OTDA was 16.1% and the specificity 90%. The 31 patients who failed OTDA were more likely to fail Vision Coach, Montreal Cognitive Assessment, and Trail Making B tests. Conclusions There was poor association between the assessment of suitability to drive by neurologists and the outcome of the OTDA in patients with brain metastases. Subtle deficits that may impair the ability to drive safely may not be evident on neurologic examination. The positive predictive value was high to predict OTDA failure. Age could be a factor affecting OTDA performance. The results raise questions about the choice of assessments in making recommendations about driving fitness in people with brain metastases. OTDA should be strongly considered in patients with brain metastases who wish to continue driving.
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway
Kothari, Vishal , Goodwin, Jonathan F., Zhao, Shuang G. , Chang, S. Laura , Evans, Joseph R. , Wilder-Romans, Kari , Gabbara, Kristina M., Dylgjeri, Emanuela , Sun, Grace Y., Tomlins, Scott A. , Mehra, Rohit , Hege, Kristen , Filvaroff, Ellen, Schaeffer, Edward M. , Karnes, R. Jeffrey , Quigley, David A. , Speers, Corey , Spratt, Daniel E. , Gilbert, Luke A. , Ashworth, Alan , Chinnaiyan, Arul M., Raj, Ganesh V. , Feng, Felix Y. , Speers, Corey , Spratt, Daniel E , Zhao, Shuang G , Drake, Justin M , Yin, Yi Ming , Chou, Jonathan , Rathkopf, Dana E , He, Housheng Hansen , Knudsen, Karen E.

Mayo Clinic

Clinical Cancer Research | July 2, 2019 | Volume: 25 | Issue: 18 | Pages: 5608-5622

10.1158/1078-0432.ccr-18-2387 | PMID 31266829 Get It

Abstract Purpose: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression. Experimental Design: To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression in vitro and in vivo. Results: DNA-dependent protein kinase (DNAPK) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of DNAPK suppressed the growth of both AR-dependent and AR-independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with DNAPK. We found that DNAPK interacts with the Wnt transcription factor LEF1 and is critical for LEF1-mediated transcription. Conclusions: Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.
Increased stride‐rate in runners following an independent retraining program: A randomized controlled trial
Baumgartner, Jesson , Gusmer, Rebecca, Hollman, John H. , Finnoff, Jonathan T. , Hollman, John , Finnoff, Jonathan T

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | July 2, 2019 | Volume: 29 | Issue: 11 | Pages: 1789-1796

10.1111/sms.13509 | PMID 31264286 Get It

PurposeIncreasing stride‐rate by 5%‐10% has been used for injury prevention and rehabilitation but evidence is limited if an independent program can alter stride‐rate in runners. The objective of this study was to determine whether the preferred stride‐rate of recreational runners can be increased by 5%‐10% following a 6‐week independent training program.MethodsThirty‐eight runners running a minimum of 15 miles/wk with a preferred stride‐rate ≤85 strides/min determined during treadmill testing were randomized into two groups: (a) Experimental group was instructed to increase stride‐rate by 10% using a watch and foot pod for stride‐rate feedback; and (b) Control group was instructed to continue normal running. Compliance was tracked with a training log. One stride being defined as two sequential steps. Preferred running stride‐rate was retested at 6 weeks using the same testing protocol.ResultsThere was no significant difference in baseline preferred running stride‐rates between the experimental or control groups. A significant (P < .001) increase in stride‐rate from 79.9 ± 4.8 to 86.8 ± 5.7 strides/min (8.6% increase) was found in the experimental group. The control group did not significantly change their stride‐rate (Baseline: 80.4 ± 4.2, 6 weeks: 81.3 ± 3.3 strides/min).ConclusionA 6‐week home training program using a watch and foot pod can increase the preferred running stride‐rate by 5%‐10% in runners with a stride‐rate of 85 or less. Clinicians may be able to apply this type of gait retraining in recreational runners when designing injury prevention and rehabilitation programs.
Evaluation of the spine is critical in the workup of recurrent instability after total hip arthroplasty
Vigdorchik, Jonathan M. , Eftekhary, Nima , Elbuluk, Ameer M. , Buckland, Aaron J. , Schwarzkopf, Ran S., Jerabek, Seth A. , Mayman, David J. , Vigdorchik, Jonathan M , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | June 30, 2019 | Volume: 101-B | Issue: 7 | Pages: 817-823

10.1302/0301-620x.101b7.bjj-2018-1502.r1 | PMID 31256675 Get It

Aims While previously underappreciated, factors related to the spine contribute substantially to the risk of dislocation following total hip arthroplasty (THA). These factors must be taken into consideration during preoperative planning for revision THA due to recurrent instability. We developed a protocol to assess the functional position of the spine, the significance of these findings, and how to address different pathologies at the time of revision THA. Patients and Methods Prospectively collected data on 111 patients undergoing revision THA for recurrent instability from January 2014 to January 2017 at two institutions were included (protocol group) and matched 1:1 to 111 revisions specifically performed for instability not using this protocol (control group). Mean follow-up was 2.8 years. Protocol patients underwent standardized preoperative imaging including supine and standing anteroposterior (AP) pelvis and lateral radiographs. Each case was scored according to the Hip-Spine Classification in Revision THA. Results Survival free of dislocation at two years was 97% in the protocol group (three dislocations, all within three months of surgery) versus 84% in the control group (18 patients). Furthermore, 77% of the inappropriately positioned acetabular components would have been unrecognized by supine AP pelvis imaging alone. Conclusion Using the Hip-Spine Classification System in revision THA, we demonstrated a significant decrease in the risk of recurrent instability compared with a control group. Without the use of this algorithm, 77% of inappropriately positioned acetabular components would have been unrecognized and incorrect treatment may have been instituted. Cite this article: Bone Joint J 2019;101-B:817–823.
Multicenter Investigation of Fungal Infections of Inflatable Penile Prostheses
Gross, Martin , Reinstatler, Lael , Henry, Gérard , Honig, Stanton, Stahl, Peter J., Maria, Pedro , Bennett, Nelson , Kava, Bruce, Köhler, Tobias , Beilan, Jonathan , Carrión, Rafael , Munarriz, Ricardo , Burnett, Arthur L. “Bud”

Mayo Clinic

The Journal of Sexual Medicine | June 26, 2019 | Volume: 16 | Issue: 7 | Pages: 1100-1105

10.1016/j.jsxm.2019.05.003 | PMID 31255212 Get It

Abstract Background Fungal infections of inflatable penile prostheses (IPPs) are inadequately understood in the literature. Aim To review a multi-institution database of IPP infections to examine for common patient and surgical factors related to IPP fungal infections. Methods This is a retrospective Institutional Review Board–approved analysis of 217 patients at 26 institutions who underwent salvage or device explant between 2001 and 2018. Patient data were compiled after an extensive record review. Outcomes 26 patients (12%) with fungal infections were identified. Results 23 of 26 patients (83%) with a fungal IPP infection were either diabetic or overweight. 15 patients had undergone primary IPP implantation, and the other 11 had previously undergone an average of 1.7 IPP-related surgeries (range 1–3; median 2). The average age at implantation was 63 years (range 31–92; median 63). 18 of the 26 patients with fungal infection had diabetes (69%), with a mean hemoglobin A1c (HbA1c) value of 8.4 (range 5.8–13.3; median 7.5). Twenty-two patients (85%) were overweight or obese. The mean body mass index for all patients was 30.1 kg/m2 (range 23.7–45 kg/m2; median 28.4 kg/m2), and that for diabetic patients was 30.8 kg/m2 (range 24.1–45 kg/m2, median 29.7 kg/m2). Ninety-one percent of implants were placed with intravenous antibiotics, consistent with current American Urological Association guidelines: an aminoglycoside plus first- or second-generation cephalosporin or vancomycin or ampicillin/sulbactam or piperacillin/tazobactam. 65% (17 of 26) of infected IPPs had only fungal growth in culture. No patient had concomitant immunosuppressive disease or recent antibiotic exposure before IPP implantation. Clinical Implications More than two-thirds of the fungal infections occurred in diabetic patients and 85% occurred in overweight or obese patients, suggesting that antifungal prophylaxis may be appropriate in these patients. Strengths & Limitations This is the largest series of fungal infections reported to date in the penile prosthesis literature. The overall number of such cases, however, remains small. Conclusion Fungal infections represent 12% of all penile prosthesis infections in our series and were seen mostly in diabetic or overweight patients, who may benefit from antifungal prophylaxis.
Distribution of Sonographically Guided Injections of the Subgluteus Minimus and Medius Bursae in Cadaveric Model
Moore, Brittany J. , Johnson, Wade O. , Smith, Jay , Sellon, Jacob L. , Finnoff, Jonathan T.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 592-592

10.1249/01.mss.0000562280.50168.94 Get It

Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study
El‐Chami, Mikhael F. , Soejima, Kyoko , Piccini, Jonathan P. , Reynolds, Dwight, Ritter, Philippe , Okabe, Toshimasa , Friedman, Paul A. , Cha, Yong‐Mei , Stromberg, Kurt , Holbrook, Reece , Fagan, Dedra H. , Roberts, Paul R. , El-Chami, Mikhael F , Stromberg, Kurt

Mayo Clinic

Pacing and Clinical Electrophysiology | June 24, 2019 | Volume: 42 | Issue: 8 | Pages: 1105-1110

10.1111/pace.13752 | PMID 31232461 Get It

AbstractBackgroundThe Micra clinical trials have enrolled more than 2500 patients without any reported device‐related infections that required removal during follow‐up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area and a greater tendency for encapsulation.ObjectiveTo analyze the incidence and outcomes of serious infectious events (SIEs: bacteremia or endocarditis) that developed during follow‐up in patients with history of Micra leadless pacemaker implantation.MethodsSIE and outcomes were characterized based upon adverse event reports. Among 720 patients implanted with Micra in the investigational device exemption trial, we identified 16 patients who had documented 21 SIEs during follow‐up.ResultsAmong patients with SIEs, mean age was 71.9 ± 11.7 years. SIEs occurred at a mean 4.8 ± 4.5 months after implant and patients were followed for 13.1 ± 9.1 months after documentation of SIE. All events were adjudicated as unrelated to the Micra device or procedure. Bacteremia was documented to be related to a gram‐positive organism in 13 events (seven Staphylococcus, three Streptococcus, two Enterococcus, and one uncharacterized gram‐positive bacteria), and gram‐negative organisms in three events. In five events, the type of organism was not characterized (two patients with endocarditis). No persistent cases of bacteremia after antibiotic cessation were seen over the duration of follow‐upConclusionIn this small series of Micra patients who developed SIEs postimplant, the occurrence of bacteremia and/or endocarditis did not appear to lead to persistent bacteremia off antibiotics; most events resolved with antibiotic treatment.
10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis
Vernat, S. Servagi, Khalifa, Jonathan , Sun, Xu-Shan, Kammerer, Emmanuel , Blais, E. , Pan, Jianji , Qiu, Hao , Bar‐Sela, Gil , Simon, Jean-Marc, Blais, Eivind , Sio, Terence Tai-Weng, Bar-Sela, Gil , Faivre, Jean Christophe , Sio, Terence T. , Simon, Jean-Marc, Salleron, Julia , Thariat, Juliette

Mayo Clinic

Cancers | June 19, 2019 | Volume: 11 | Issue: 6 | Pages: 849

10.3390/cancers11060849 | PMID 31248183 Get It

(1) Background: To assess the role of postoperative external beam radiotherapy (pEBRT) on locoregional failure (LRF) for patients with locally advanced high-risk non-anaplastic thyroid carcinoma (naTC) at primary event or relapse. (2) Methods: Between 1995 and 2015, postoperative naTC patients with a theoretical indication for EBRT were included based on criteria that were common to American-British-French current guidelines, i.e., pT3-4, pN+, gross or microscopic residual disease. Inverse probability of treatment weighting (IPTW) after multiple imputation was used to reduce selection biases. (3) Results: Of 254 naTC patients, 216 patients underwent pEBRT (106 de novo, 110 at relapse, median dose 60 Gy) and 38 underwent surgery only. pEBRT patients had more gross residual disease, a major prognostic factor (p = 0.027) but less perineural invasion (p = 0.008) or lymphovascular emboli (p = 0.009). pEBRT patients more frequently underwent radioiodine therapy (p = 0.026). The 10-year cumulative incidence of LRF was 56% (95% CI, 32–74%) in operated patients, and 23% (95% CI, 17–30%) in pEBRT patients. After IPTW method, pEBRT reduced the risk of LRF (hazard ratio 0.30; 95% CI [0.18–0.49], p < 0.001), but had no impact on OS. In the pEBRT group, non-Intensity Modulated RadioTherapy (IMRT) plans and interruption of the radiotherapy were associated with poorer survival, while extended versus limited field strategy and dose were not. (4) Conclusions: In naTC patients who have pT3-4, pN+ disease or R1-2 resection, pEBRT improved LRF. Limited-field IMRT is preferred.